Cargando…

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy

BACKGROUND: Contemporary data of peripheral T‐cell lymphoma (PTCL) and natural‐killer/T‐cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited. AIMS: We performed a retrospective analysis to estimate outcomes of ICE‐treated PTCL and NKTL patients at three...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tay, Tricia, Somasundaram, Nagavalli, Lim, Cindy, Khoo, Lay Poh, Goh, Allan Zhi Kai, Lee, Yuh Shan, Liu, Xin, Tao, Miriam, Quek, Richard, Farid, Mohamad, Poon, Eileen, Chan, Jason Y. S., Chang, Esther W. Y., Yang, Valerie S. W., Goh, Yeow Tee, Tan, Daryl, Diong, Colin, Grigoropoulos, Nicholas F., Nagarajan, Chandramouli, Poon, Michelle, de Mel, Sanjay, Jeyasekharan, Anand, Chan, Esther H. L., Lee, Joanne, Chee, Yen Lin, Lim, Soon Thye, Tang, Tiffany
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458502/ https://www.ncbi.nlm.nih.gov/pubmed/35481622 http://dx.doi.org/10.1002/cnr2.1552

Ejemplares similares

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations
por: Chan, Jason Yongsheng, et al.
Publicado: (2023)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population
por: Yang, Xinyi, et al.
Publicado: (2021)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era
por: Lim, Ryan Mao Heng, et al.
Publicado: (2020)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma
por: Bücklein, Veit, et al.
Publicado: (2020)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin’s Lymphoma
por: Tan, Grace Fangmin, et al.
Publicado: (2023)

Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review
por: Yap, Daniel Ren Yi, et al.
Publicado: (2020)

Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
por: Tan, Jing Yuan, et al.
Publicado: (2021)

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
por: Somasundaram, Nagavalli, et al.
Publicado: (2019)

Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort
por: Tan, Laura Ling Ying, et al.
Publicado: (2020)

Valsalva-Like Retinopathy Secondary to Pancytopenia following Induction of Etoposide and Ifosfamide
por: Prinzi, Robert A., et al.
Publicado: (2015)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma
por: Chan, Esther Hian Li, et al.
Publicado: (2019)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Carboplatin/etoposide: Neutropenia and thrombocytopenia: case report
Publicado: (2021)

A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System Lymphoma
por: Lo, Yu Tung, et al.
Publicado: (2022)

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma
por: Tomono, Ayana, et al.
Publicado: (2016)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
por: Chen, Yunxin, et al.
Publicado: (2021)

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series
por: Aiba, Hisaki, et al.
Publicado: (2023)

Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma
por: Chan, Jason Yongsheng, et al.
Publicado: (2018)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_18invft29bmpqcasjbp75rgbth